DOCSLIB.ORG

I Ha Un Torn Datuk Umum Mundial Month

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
I Ha Un Torn Datuk Umum Mundial Month IHA UN TORN DATUKUMUMUS 20170258927A1 MUNDIAL MONTH ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0258927 A1 Johnston (43 ) Pub . Date : Sep . 14 , 2017 ( 54 ) FORMULATIONS AND DOSES OF Publication Classification PEGYLATED URICASE (51 ) Int . CI. A61K 31/ 4355 ( 2006 .01 ) (71 ) Applicant : Selecta Biosciences , Inc ., Watertown, A61K 9 /00 ( 2006 . 01) MA (US ) A61K 31/ 436 (2006 . 01 ) A61K 38 / 44 ( 2006 .01 ) ( 72 ) Inventor: Lloyd Johnston , Belmont, MA (US ) A61K 9 / 16 ( 2006 . 01 ) (21 ) Appl. No. : 15 /456 , 520 A61K 39 / 00 (2006 . 01) (52 ) U .S . CI. (22 ) Filed : Mar. 11 , 2017 CPC . .. .. .. A61K 47/ 48215 ( 2013 .01 ) ; A6IK 38 / 44 (2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ; A61K Related U . S . Application Data 9 / 1647 (2013 . 01 ) ; A61K 31/ 436 (2013 .01 ) (60 ) Provisional application No . 62 /442 , 948 , filed on Jan . 5 , 2017 , provisional application No . 62/ 430 , 547 , filed (57 ) ABSTRACT on Dec . 6 , 2016 , provisional application No. 62 / 403 , 664, filed on Oct. 3 , 2016 , provisional application No. Provided herein are methods and compositions and kits 62 /398 , 422 , filed on Sep . 22 , 2016 , provisional appli related to uricase compositions and /or compositions com cation No. 62 /397 ,832 , filed on Sep . 21 , 2016 , pro prising synthetic nanocarriers comprising an immunosup visional application No . 62 / 346 , 348 , filed on Jun . 6 , pressant . Also provided herein are methods and composi 2016 , provisional application No . 62 /339 , 944 , filed tions and kits for the treatment of subjects , including on May 22 , 2016 , provisional application No . 62/ 307 , subjects with hyperuricemia , gout or a condition associated 412 , filed on Mar. 11 , 2016 . with gout, and for preventing gout flare. Patent Application Publication Sep . 14, 2017 Sheet lof9 US 2017 / 0258927A1 Fig . 1 Patent Application Publication Sep . 14 , 2017 Sheet 2 of 9 US 2017 /0258927 A1 Fig. 2 wwwwwwwwwwwSVP . Rapamycinw wwwwwwwww Pegsiticase Rapamycin Pro try Hyttines PLA + PLA -PEG * " # SPAN 40 Patent Application Publication Sep . 14 , 2017 Sheet 3 of 9 US 2017 /0258927 A1 Fig . 3 Treatment Challenge Empty Nanoparkle Brescicax easticas SVA 230myon oix Dessiticase ogsittcase SVK 28axias D osien Festa?? ?? ???? ?? ?? ???? * * * * TI* Osy 1 29 53 13 341 * ** ** BOLVO¥sweds **** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * wiwiwinin miningnan nimiiniin Qays Patent Application Publication Sep . 14 , 2017 Sheet 4 of 9 US 2017 /0258927 A1 Fig . 4 Cose love cohorts pbupovouUKS 11.16 th ** lothing min www o . .. .. .. Days post infusion Patent Application Publication Sep . 14 , 2017 Sheet 5 of 9 US 2017 /0258927 A1 Fig . 5 Subject Phase 1a Cohort # 3 Wocid AOA :289 ADA ADA BO ABAT AON TEC Criteris 1398 miten se (Tan s k ( item and Mon 920NA 32853 NA ??????? Phase 1b Cohort # 9 Suseet O ADA ADA U XOA 104 ADA ( htenstein und in einen hohen * * * * * * * * * * * * * * 44444444 VA 33 3330 ha n nsson Barine Day 7 Day 14 Day 2 Day 1 Subiec Phase 1b Cohort # 4 200gr AQA osigade 80 % e com ADA AQA AOA * ** ** * * ** * * * NA 9180 2836 Subject Day 7 Or 39 Day 2 Day 30 wie AOA AOA ADA ORADA 204 Phase 1b Cohort # 6 www Tisno od mene titen Tong Tilen wwwww Soubound Nagu Negative: Na . = Sample not available ) Patent Application Publication Sep . 14 , 2017 Sheet 6 of 9 US 2017 /0258927 A1 Fig . 6 Phase 1a Cohort # 3 and Phaseja Cohort3 aosudoues #Boko Phase 1a1b CohortCohort #39 and Pegsiticage only Phase 1b Cotorts # 1 , # 3 and # S (SVR -Rapamyon only ) wwwwwwwwwwwwwwwwwwwwwwwwwwwww Phase 10 cohort # 2 S * * * * * (SEL - 212 ) Phase1bCohorts#1,2345and SerumUrloadd(mooL Phase 16 Cohort 4 ?????????????????????? . W * (SEL - 212 ) ? Phase 1o Cohort # 6 Bom (SEL212 ) wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww . 12 Patent Application Publication Sep . 14 , 2017 Sheet 7 of 9 US 2017 /0258927 A1 Fig . 7 Krystexxa Pegsiticase SEL -212 * Piacevo neck- ofesyoxdur Rasadnia SVP papaixo Meanuricadd,midi Down finnst y Cat 5 * brand innovativeanesquisa Resets Fogsitinn . *wwwwwww Rom . + + + + + + + . *** * Weeks Weeks WERKS s exceptions O to me to site dose rossowy 22 Cms Koema 38 Smye AKA 208 V 30877 Patent Application Publication Sep . 14 , 2017 Sheet 8 of 9 US 2017 /0258927 A1 Fig . 8 Serum Uric Acid Levels by Cohort SVP -Rapamycin only $ ( 0 .038 , 0 . 1 , and 0 . 3 amg/ kg ) * * Pegsiticase only * ** ** * * * ( 0 . 4mg/ kg ) ** * * * ** * * SerumUricAcid(mg/dL) SEL - 212 ( 0 .03mg / kg SVP -Rapamycin + 0 .4mg / kg pegsiticase ) . .. SEL- 212 (0 . 1mg/ kg SVP -Rapamycin .. .. .. .. .. .. .. + 0 .4mg / kg pegsiticase ) * . - - - - - - - SEL - 212 ( 0 . 3mg/ kg SVP -Rapamycin . .. .. .. + 0 . 4mg/ kg pegsiticase ) O 7 14 21 30 Day Day 30 SUA levels and ADA levels Pegsiticase alone SEL - 212 SEL - 212 ( 0 . 4 mg/ kg ) 0 . 3 mg/ kg SVP -Rapamycin 0 . 3 mg/ kg SVP -Rapamycin + 0 . 4 mg/ kg Pegsiticase + 0 . 4 mg/ kg Pegsiticase Day 30 Subject Day 30 Subject Day 30 Subject Unic acid ADA Uric acid ADA number Unc acid ADA number med (Titer ) number mad ) (Titer ) (mg / dL ) ( Titer) 108 -0010 N 1080 107 - 0018300018 : Neo 107 -0027 0 Neo 103- 0015 6 9720 107 -0021 Nec 107 - 0028 Mag 104 -0032 19 1080 104 - 0027 64 29160 104 - 0050 Neg 109- 0012 1080 108 - 0008 0 : 1 104 - 0060 120 | 104 -0036 880 9720 | 102- 0005 | < 0 . 1 Nes 103 - 0019 Neg (Neg = Negative ) Patent Application Publication Sep . 14 , 2017 Sheet 9 of 9 US 2017 /0258927 A1 Fig. 9 Cohort SEL - 110 SEL -037 junto NA 10. 2 mg/ kg 0 .4 mg/ kg N 0 . 05mg/ kg | 0 . 2 mg/ kg 0 .05mg kg 0 . 4 mg / k & 0 .08mg / kg 0 . 2 mg/ kg 0 .08mg / kg 0 . 4 mg / kg www US 2017 /0258927 A1 Sep . 14 , 2017 FORMULATIONS AND DOSES OF ing uricase provided herein alone or in combination with any PEGYLATED URICASE one of the compositions comprising synthetic nanocarriers comprising an immunosuppressant provided herein . In one RELATED APPLICATIONS embodiment of any one of the methods provided herein , the compositions comprising uricase provided herein alone or in [0001 ] This application claims the benefit ofpriority under combination with any one of the compositions comprising 35 U . S . C . $ 119 of U . S . provisional applications 62 /307 ,412 synthetic nanocarriers comprising an immunosuppressant filed Mar . 11 , 2016 ; 62 / 339 , 944 filed May 22 , 2016 ; 62 / 346 , may be repeatedly administered to the subject. The subject 348 filed Jun . 6 , 2016 ; 62 /397 ,832 filed Sep . 21 , 2016 ; may be one in need thereof. The subject may be any one of 62 /398 ,422 filed Sep . 22 , 2016 ; 62/ 403 , 664 filed Oct. 3 , the subjects described herein . 2016 ; 62 /430 ,547 filed Dec . 6 , 2016 ; and 62/ 442 ,948 filed [0006 ] In one aspect, a method of treating a human subject Jan . 5 , 2017 , the entire contents of each of which are with gout or a condition associated with gout, comprising incorporated herein by reference . administering to the subject a composition comprising FIELD OF THE INVENTION uricase and a pharmaceutically acceptable carrier is pro vided . In one embodiment, the administration is via a [ 0002 ] Provided herein are methods and compositions and non - intramuscular mode of administration . In one embodi kits related to uricase compositions and /or compositions ment, the composition comprising uricase and a pharmaceu comprising synthetic nanocarriers comprising an immuno tically acceptable carrier is administered more than once to suppressant. Also provided herein are methods and compo the subject . In one embodiment, the composition comprising sitions and kits for the treatment of subjects , including uricase and a pharmaceutically acceptable carrier is admin subjects with hyperuricemia , gout or a condition associated istered more than twice , more than thrice , or more than four with gout, and for preventing gout flare . times to the subject. In one embodiment, the composition comprising uricase and a pharmaceutically acceptable car SUMMARY OF THE INVENTION rier is administered every two to four weeks . In one embodi [0003 ] The development of anti - drug antibodies (ADAS ) ment, the composition comprising uricase and a pharmaceu is a common cause for biotherapeutic treatment failure and tically acceptable carrier is administered monthly. In one adverse hypersensitivity reactions . It has been demonstrated embodiment, the composition comprising uricase and a that synthetic nanocarriers comprising an immunosuppres pharmaceutically acceptable carrier is administered con sant are capable of inducing immunological tolerance to a comitantly with a composition comprising an immunosup composition comprising uricase , resulting in improved effi pressant. cacy of the uricase - comprising composition . The improved [ 0007 ] In one aspect, a method of treating a subject with efficacy has been demonstrated at least with a significantly gout or a condition associated with gout, comprising con higher rate of reduction in serum uric acid levels over time comitantly administering to the subject a composition com as compared to other treatments . It has also been demon prising synthetic nanocarriers comprising an immunosup strated that synthetic nanocarriers comprising an immuno pressant and a composition comprising uricase is provided . suppressant, when administered concomitantly with a com [0008 ] Also provided herein are methods of treating a position comprising uricase , are capable of significantly subject that may experience gout flare comprising adminis reducing the incidence of gout flare as compared to other tering any one of the compositions
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Alternatives to Allopurinol Hyper-Responsiveness to EBV In
    Ann Rheum Dis: first published as 10.1136/ard.46.6.493-a on 1 June 1987. Downloaded from Correspondence 493 2 Ropes M W. Bennett G A. Cobb S. Jacox R. Jessar R A. 6 Auscher C. Pasquier C. Mercier N. Delbarre F. Oxidation of Revision of diagnostic criteria for rheumatoid arthritis. Bull pyrazolo (3.4-d) pyrimidine in a xanthinuric man. Isr J Med Sci Rheu,n Dis 1958: 9: 175-6. 1973: 9: 3. 3 Nepom G T. Seyftied C E. Holbeck S L. Wilske K R. 7 Elion G B. Benezra F M. Caneilas 1. Carrington L 0. Hitchings Nepom B S. Identification of HLA-DwI4 genes in DR4+ G H. Effects of xanthine oxidase inhibitors on purine meta- rheumatoid arthritis. Lancet 1986: ii: 1(0)2-5. bolism. Isr J Clzetn 1968; 6: 787-96. 8 Rundles R W. Metz E N. Silberman H R. Allopurinol in the treatment of gout. Aiiii ltiter,i Med 1966: 64: 229-58. 9 Delbarre F. Amor B. Auscher C. De Gery A. Treatment of gout with allopurinol: a studv of 1t)6 cases. Ann,l Rheutn Dis Alternatives to allopurinol 1966: 25: 627-33. 10 Rundles R W. Metabolic effects of allopurinol and In their letter to the Annals Kelsey et al state that alloxanthine. Atiti Rheu,n Dis 1966: 25: 615-2). SIR, 11 Lockard 0 Jr, Harmon C. Nolph K. Irvin W. Allergic reaction there is 'no available alternative to allopurinol with its to allopurinol with cross-reactiyity to oxypurinol. Ann Intern unique mode of action'.' There are at least two alter- Med 1976; 85: 333-5.
    [Show full text]
  • Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease (TROFEO Trial)
    Circ J 2017; 81: 1707 – 1712 ORIGINAL ARTICLE doi: 10.1253/circj.CJ-17-0438 Preventive Medicine Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial) Akira Sezai, MD, PhD; Kazuaki Obata; Keisuke Abe; Sakie Kanno; Hisakuni Sekino, MD, PhD Background: We previously reported that febuxostat was more effective for hyperuricemia than allopurinol. The efficacy, however, of topiroxostat (a novel xanthine oxidase reductase inhibitor similar to febuxostat), for hyperuricemia is unknown. Methods and Results: Patients with cardiovascular disease and hyperuricemia, in whom serum uric acid (s-UA) was controlled at ≤6 mg/dL, were eligible for enrollment. Fifty-five patients were randomized to receive either febuxostat or topiroxostat for 6 months and were switched to the other drug for the following 6 months. The primary endpoint was s-UA. Secondary endpoints included serum creatinine, estimated glomerular filtration rate, urinary albumin, cystatin-C, oxidized low-density lipoprotein, eicosapentaenoic acid/ arachidonic acid ratio, lipid biomarkers, high-sensitivity C-reactive protein and B-type natriuretic protein. Although s-UA level was similar for both drugs, significantly more patients required dose escalation during treatment with topiroxostat. There were no differ- ences in renal function, inflammatory and lipid markers between the 2 drugs. A biomarker of oxidative stress was significantly lower after 3 months of febuxostat compared with topiroxostat. Conclusions: Febuxostat causes more marked and more rapid reduction of s-UA than topiroxostat. With regard to the antioxidant effect, febuxostat was superior to topiroxostat after 3 months. The renal protective and anti-inflammatory effects of both drugs were also similar after 6 months of treatment.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Report on the Deliberation Results May 8, 2013 Evaluation And
    Report on the Deliberation Results May 8, 2013 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] (a) Topiloric Tablets 20 mg, 40 mg, and 60 mg (b) Uriadec Tablets 20 mg, 40 mg, and 60 mg [Non-proprietary name] Topiroxostat (JAN*) [Applicant] (a) Fujiyakuhin Co., Ltd. (b) Sanwa Kagaku Kenkyusho Co., Ltd. [Date of application] June 26, 2012 [Results of deliberation] In the meeting held on April 26, 2013, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product, the re-examination period is 8 years, and neither the drug substance nor the drug product is classified as a poisonous drug or a powerful drug. *Japanese Accepted Name (modified INN) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Review Report April 15, 2013 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product submitted for registration are as follows. [Brand name] (a) Topiloric Tablets 20 mg, 40 mg, and 60 mg (b) Uriadec Tablets 20 mg, 40 mg, and 60 mg [Non-proprietary name] Topiroxostat [Applicant] (a) Fujiyakuhin Co., Ltd.
    [Show full text]
  • Metrochem API Private Limited
    Metrochem API Private Limited APIs USDMF / CEP Numbers Submission Date Status Written Confirmation Acotiamide Alogliptin Benzoate Antazoline HCL CEP 2020-060 10 February,2020 Antazoline Phosphate USDMF 34330 1 January,2020 Apixaban USDMF 35518 30 December,2020 Apremilast Azilsartan Baloxavir Marboxil Product Under Validation Bempedoic Acid Bepotastine Besilate Bilastine Canagliflozin Cenobamate Cinitapride Clopidogrel Bisulfate Form I USDMF 34334 5 February,2020 Indian CDSCO WC-0493 Clopidogrel Bisulfate Form II USDMF 34334 5 February,2020 Indian CDSCO WC-0493 Crisaborole Dabigatran Dapaglifloin Amorphous Dapagliflozin Dexketoprofen Trometamol USDMF 34732 21 March,2020 Indian CDSCO WC-0493 Dexlansoprazole USDMF 34971 29 September,2020 Dexrabeprazole Dimethindene Maleate CEP 2021-080 6 February,2021 Edoxaban Efinaconazole Elagolix Elobixibat Product Under Validation Eltrombopag Empagliflozin USDMF 35345 31 October,2020 Indian CDSCO WC-0493 Empagliflozin Amorphous Ertugliflozin Esomeprazole Magnesium Dihydrate USDMF 35519 ; CEP 2021-022 29 December,2020 ; 28 December 2020 Note: None of the products will be supplied to the countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purpose only. However, the final responsibility exclusively lies with the buyer. Metrochem API Private Limited APIs USDMF / CEP Numbers Submission Date Status Written Confirmation Esomeprazole Magnesium Trihydrate USDMF 35400 ; CEP 2020-386 28 November,2020 ; 21 November,2020 Esomeprazole Sodium
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]